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Abstract

Author Manuscript

Background—Although cognitive deficits in patients with schizophrenia are rooted early in
development, the impact of psychosis on the course of cognitive functioning remains unclear. In
this study a nested case-control design was used to examine the relationship between emerging
psychosis and the course of cognition in individuals ascertained as clinical high-risk (CHR) who
developed psychosis during the study (CHR+T).
Method—Fifteen CHR+T subjects were administered a neurocognitive battery at baseline and
post-psychosis onset (8.04 months, S.D. = 10.26). CHR+T subjects were matched on a case-bycase basis on age, gender, and time to retest with a group of healthy comparison subjects (CNTL,
n = 15) and two groups of CHR subjects that did not transition: (1) subjects matched on
medication treatment (i.e. antipsychotics and antidepressants) at both baseline and retesting
(Meds-matched CHR+NT, n = 15); (2) subjects unmedicated at both assessments (Meds-free CHR
+NT, n = 15).
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Results—At baseline, CHR+T subjects showed large global neurocognitive and intellectual
impairments, along with specific impairments in processing speed, verbal memory, sustained
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attention, and executive function. These impairments persisted after psychosis onset and did not
further deteriorate. In contrast, CHR+NT subjects demonstrated stable mild to no impairments in
neurocognitive and intellectual performance, independent of medication treatment.
Conclusions—Cognition appears to be impaired prior to the emergence of psychotic symptoms,
with no further deterioration associated with the onset of psychosis. Cognitive deficits represent
trait risk markers, as opposed to state markers of disease status and may therefore serve as possible
predictors of schizophrenia prior to the onset of the full illness.
Keywords
Clinical high risk; linear mixed-effects models; nested case-control study; neurocognition;
prodromal; psychosis
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Introduction

Author Manuscript

Cognitive deficits have long been considered core features of schizophrenia and other
psychotic disorders (Elvevag & Goldberg, 2000; Green et al. 2004; Keefe & Harvey, 2012).
Deficits in processing speed and verbal memory, for example, pervasively endure
throughout the lifespan and are major contributors of the profound disability that is
associated with the illness (Green & Harvey, 2014). However, the role of impaired cognition
in the onset of psychosis is not yet fully understood and is an issue of central importance in
the possible prevention of illness. A key unresolved etiological question is whether cognitive
deficits represent long-standing traits that are part of the lifelong vulnerability to
schizophrenia or, alternately, whether the emergence of psychotic symptoms causes a
noticeable drop in cognitive functioning (McGlashan, 2006). Although considerable data
suggest that impaired cognition is in fact neurodevelopmental in nature (Cornblatt et al.
1999; Zipursky et al. 2013; Bora, 2015) with problems detectable early in life (Cannon et al.
2000), there is a persistent view in the literature that cognition follows a neurodegenerative
course through the progression of psychotic illness (Bilder et al. 1992; Gold, 1998), Since
neurocognition provides a window into brain functioning, understanding the course of
cognitive functioning in schizophrenia may provide an opportunity of reducing risk for later
psychosis (Cornblatt et al. 2003; Lencz et al. 2006; Pukrop et al. 2007; Michel et al. 2014).
Therefore, the goal of the current report was to prospectively examine the course of
neurocognition before and after the transition to psychosis in a group of individuals initially
ascertained as clinical high-risk (CHR, i.e. putative prodrome to psychosis).

Author Manuscript

Although it is well-documented that cognitive deficits are rooted early in neurodevelopment
(Cannon et al. 2000; Fusar-Poli et al. 2012a), earlier cross-sectional studies with patients
with first-episode psychosis (FEP) found less severe neuropsychological deficits compared
to chronically ill patients (Schwartzman & Douglas, 1962; Bilder et al. 1992), suggesting
that deterioration may have occurred after the onset of psychotic symptoms. The crosssectional design, however, makes it difficult to tease apart true progressive changes after
illness onset, as the recruitment of chronic patients may be biased toward participants with
poorer neurocognition (Keshavan et al. 2005). Similarly, older patients with a chronic
course of schizophrenia are more likely to be recruited from services that provide ongoing
treatments for poor outcomes and disability. More recent cohort studies have found evidence
Psychol Med. Author manuscript; available in PMC 2016 May 01.
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of altered neurocognitive trajectories in individuals that developed schizophrenia relative to
those who did not develop the schizophrenia (Reichenberg et al. 2002, 2010; Caspi et al.
2003; Meier et al. 2014). Meier et al. (2014) for example, demonstrated a decline in
cognitive performance in individuals who developed schizophrenia repeatedly tested from
childhood through adulthood (at age 38) after illness onset.

Author Manuscript

While these findings suggest neurocognitive deterioration over the course of illness
progression, determining the exact timing of the decline is relatively difficult. Cognitive
decline could have occurred during the prodromal period, during the first episode, or after
the onset of psychosis (Seidman et al. 2006; Bora, 2014). In addition, inconsistent
neuropsychological test batteries over the course of a longitudinal study further complicates
determining whether or not the onset of psychosis, per se, causes further deterioration in
cognitive performance (Bora, 2014). Moreover, the impact of the onset and development of
psychosis, in and of itself, on the course of cognition in the earliest stages of the illness
remains unclear.

Author Manuscript

Looking to overcome these problems and address the specific issue of whether the onset of
psychosis causes further deterioration in cognition, recent studies have prospectively
followed individuals that are earlier in the course of illness and are at CHR for developing
psychosis. These adolescents and young adults with increasing attenuated positive
symptoms are in a critical phase of illness progression and developmental brain maturation
processes that may contribute to the pathogenesis of the illness. To date, several CHR
studies (Keefe et al. 2006; Wood et al. 2007; Hawkins et al. 2008; Becker et al. 2010;
Jahshan et al. 2010; Woodberry et al. 2013) have examined the course of cognitive
functioning in individuals transitioning to psychotic disorders (i.e. converters) during
prospective follow-up. For example, Wood et al. (2007) found that individuals who
progressed to full-blown psychosis showed a decline over the follow-up period on measures
of visual memory and attentional set-shifting. Similarly, Woodberry et al. (2013) also found
a progressive impairment in verbal memory in those who transitioned to psychosis. In
contrast, Becker et al. (2010) reported no deterioration after the onset of psychosis, with
large and stable impairments for converters in verbal memory and processing speed.

Author Manuscript

These inconsistencies may be related to several factors. First, many studies do not account
for certain factors that are known to impact the neurodevelopment trajectory of the illness,
like gender (Walder et al. 2013) and age (Glahn et al. 2013). Second, the duration of time
between assessments could partially explain differences between those who develop
psychosis and those who did not (Becker et al. 2010). Participants not developing psychosis
during the study are tested at regular and pre-determined intervals (e.g. 12 and 24 months).
In contrast, the development of psychosis and the post-psychosis neurocognitive assessment
can occur at any time between regularly scheduled assessments resulting in different
practice effects. Lastly, the impact of medication treatment with antipsychotics and
antidepressants on cognition in CHR subjects who develop psychosis is unclear. This last
issue is an important point of consideration given that previous work from our group (Bowie
et al. 2012) found that antipsychotic treatment was associated with worse neurocognitive
performance in high-risk subjects over a short amount of time. Furthermore, cumulative
exposure to anti-psychotic treatment in schizophrenia may be significantly associated with
Psychol Med. Author manuscript; available in PMC 2016 May 01.
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changes in brain structure and function over time (Fusar-Poli et al. 2013). This is
particularly problematic in high-risk samples as true positives are treated with a higher
proportion of antipsychotics (Cannon et al. 2008; Ruhrmann et al. 2010), further
confounding the relationship between the onset of psychosis and neurocognition. For
example, while Hawkins et al. (2008) found a post-psychosis decline in motor speed,
treatment with olanzapine was initiated in the CHR subjects who developed psychosis prior
to the post-conversion assessment making it difficult to attribute the decline to the onset of
psychosis.

Author Manuscript

In order to determine whether the neurocognitive deficits that characterize schizophrenia are
stable traits, present prior to the onset of psychosis, or manifest due to emergence of
psychosis, the course of neurocognition was examined in individuals initially ascertained as
CHR who transitioned to psychosis over the course of the prospective study (i.e. converters).
The neurocognitive performance of the CHR converters was examined pre-psychosis (i.e.
baseline assessment) and shortly after the onset of psychosis and compared to CHR subjects
who did not develop psychosis and healthy control subjects. A nested case-control design
was conducted to avoid the possible confounding effects of age, gender, time between
assessments, and medication treatment. Based on recent meta-analytic data that FEP patients
show no deterioration in neurocognitive performance relative to pre-morbid levels (Bora &
Murray, 2014) we hypothesized that cognitive deficits in true positives (CHR subjects who
developed psychosis) would be apparent prior to the onset of psychosis and would remain
stable after post-psychosis onset with no deterioration despite the emergence of psychosis.

Method
Design

Author Manuscript

In this nested case-control study, the CHR subjects who transitioned to psychosis (CHR+T)
were assessed before and after the onset of psychosis. CHR+T subjects were matched to two
groups of CHR subjects who did not transition to psychosis (CHR+NT). The first group of
CHR+NT subjects were matched for age, gender, baseline severity of positive symptoms,
time to retest, and medication status (antipsychotic and antidepressant) at baseline and retest.
The second group of CHR+NT subjects were matched for the same demographic and
clinical variables, but were unmedicated at both baseline and retest. Healthy controls were
also included to assess practice effects. The nested design allowed us to address: (1)
cognitive changes over time in subjects who developed psychosis (CHR+T); and (2) practice
effects of matched CHR+NT subjects, unrelated to psychosis, medication, age, gender, and
time to retest.

Author Manuscript

Participants
This paper reports retest data for participants recruited during Phase 1 (2000–2006) and
Phase 2 (2006–2012) of the Recognition and Prevention (RAP) Program, an ongoing
longitudinal investigation initiated in 1998 and funded by the National Institute of Mental
Health in 2000. Patient referrals were made to the RAP Program by affiliated outpatient and
inpatient psychiatry departments, local mental health providers, school psychologists or
counselors, or were self-referred. All procedures were approved by the Institutional Review

Psychol Med. Author manuscript; available in PMC 2016 May 01.
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Board at the North Shore-LIJ Health System. Written informed consent (with assent from
participants aged <18 years) was obtained from all participants.
Forty-five participants meeting criteria for Clinical High-Risk, Positive (CHR+) derived
from the Scale of Prodromal Symptoms (SOPS; Miller et al. 1999, 2002, 2003) were
included in this nested sub-sample. Inclusion criteria were based on the presence of one or
more moderate, moderately severe, or severe (scores of 3, 4, or 5) SOPS rated attenuated
positive symptoms (scale 0–6). A score of 6 (severe and psychotic) on any item was an
exclusion factor for the CHR group. In this paper, subjects in the CHR+ group are broadly
comparable to those considered ‘prodromal’ in most other studies in North America and
internationally (Correll et al. 2010).

Author Manuscript

Recruitment in Phase 1 and Phase 2 yielded a total of 240 CHR+ participants. The current
nested sub-sample included 15 CHR+T subjects out of a total of 23 CHR+T subjects who
developed a psychotic disorder. Eight CHR+T subjects were excluded for not having both a
pre- and post-psychosis onset neuropsychological assessment. Matches for the CHR+T
subjects were selected from a total pool of 217 CHR+NT subjects. Of the 217 CHR+NT
subjects, 188 had a baseline and at least one follow-up visit. Forty CHR+NT subjects were
unmedicated at both testing points and a total of 148 were medicated at either the baseline or
retest assessment. The sample selection process is outlined in Supplementary Fig. S1.

Author Manuscript

The 15 CHR+T subjects in the current study were tested at both time 1 (baseline, before
psychosis) and time 2 (retest, post-psychosis). Mean time to conversion was 12.34 months
(S.D. = 16.06, median = 8.31). The mean time between conversion and the post-conversion
retest was 8.14 months (S.D. = 10.19, median = 3.55). Diagnoses at the last follow-up
evaluation included: schizophrenia (n = 6), psychosis not otherwise specified (n = 5), bipolar
I disorder, most recent episode manic, severe with psychosis (n = 3), delusional disorder,
persecutory type (n = 1).
CHR+T subjects were matched on a case-by-case (1:1 ratio) with two groups of CHR+NT
subjects: (1) Meds-matched CHR+NT subjects (n = 15) matched on medication treatment
(i.e. antipsychotics, anti-depressants) at both baseline and retesting; (2) Meds-free CHR+NT
subjects (n = 15) unmedicated at both assessments. The CHR+T subjects were also matched
in a 1:1 ratio with healthy comparison subjects (CNTL; n = 15). All four subject groups
were therefore matched on gender, age (±1-year window), and time to retest (±4-month
window). All subjects on medication at testing were receiving stable doses for at least 2
weeks prior to the assessment.

Author Manuscript

CNTLs were recruited through announcements in local newspapers and within the medical
center. Inclusion criteria required participants to be between the ages of 12 and 22 years.
Exclusion criteria for all participants included: (1) schizophrenia-spectrum diagnosis; (2)
non-English speaking; (3) a medical or neurological disorder; (3) estimated IQ < 70. Healthy
controls with a first-degree relative with a diagnosed Axis I psychotic disorder were also
excluded.

Psychol Med. Author manuscript; available in PMC 2016 May 01.
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Axis I diagnoses were assessed by the Schedule for Affective Disorders and Schizophrenia
for School-Age Children, Epidemiologic Version (K-SADS-E; Orvaschel & Puig-Antich,
1994). Prodromal symptoms were assessed by the Structured Interview for Prodromal
Syndromes (SIPS) and the companion SOPS (Miller et al. 1999). Conversion to psychosis
was defined as the presence of a psychotic level positive symptom (score of 6 on the SOPS).
The K-SADS-E was used to confirm diagnoses in those participants whose symptoms
developed into full psychotic disorders. Social and role functioning was assessed using the
GF: Social and GF:Role scales (Cornblatt et al. 2007). The GF:Social scale assesses peer
relationships, peer conflict, age-appropriate intimate relationships, and involvement with
family members. The GF:Role scale rates performance and amount of support needed in
one’s specific role (i.e. school, work).

Author Manuscript

Baseline neurocognitive assessment
Patients were administered a comprehensive battery of tests that took approximately 3.5 h to
complete at study entry. Testers were at the master’s level or above and trained in the
administration and scoring of all tests. Estimated full-scale IQ scores were derived from the
Vocabulary and Block Design subscales of the Wechsler Intelligence Scale for Children, 3rd
edition (WISC-III; Wechsler, 1991) for subjects aged <16 years and from the same
subscales of the Wechsler Adult Intelligence Scale, Revised (WAIS-R; Wechsler, 1981) for
subjects aged ≥16 years.

Author Manuscript
Author Manuscript

In addition to the intelligence tests, the baseline and retest batteries included
neuropsychological tests that assessed six cognitive domains (see Table 1): processing
speed, verbal memory, executive function, working memory, sustained attention, and
language. Domain construction was based on: (1) rational criteria derived from previous
findings in patients with schizophrenia that demonstrated separable neurocognitive factors
(Green et al. 2004) and; (2) previous work with subjects at CHR that demonstrated the
content validity of the domains (see Seidman et al. 2010; Carrión et al. 2011, 2013 for more
details). Prior to neurocognitive domain construction, raw test scores were log-transformed
to reduce skewness and improve the distribution. Extreme values (±3.5 S.D.) were
Winsorized to reduce the impact of outliers.(Dixon & Tukey, 1968) Test scores were then
transformed into standard Z scores using the age-stratified means and S.D.s of a larger group
of CNTLs (n = 114) to control for age-related change in cognitive performance. When
applicable, tests were reverse-scored so that lower scores reflected worse performance.
Domain scores were computed by averaging each subject’s Z scores on tests assessing the
same neurocognitive domain. Z scores for each domain were then re-standardized using the
mean and S.D. of the domain scores of the healthy comparison group. A composite of global
neurocognitive performance was calculated by averaging the neurocognitive domains.
Statistical analyses
All analyses were conducted using SPSS 16.0 (SPSS Inc., USA). Comparisons of
demographic and clinical characteristics were performed with Student’s t tests for
continuous variables, Pearson’s χ2 or Fisher’s exact tests for categorical variables, and
Kolmogorov–Smirnov Z for one ordinal variable (two-tailed, p < 0.05). Linear mixed-effects
Psychol Med. Author manuscript; available in PMC 2016 May 01.
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models for repeated measures were used to compare the neurocognitive performance of the
four subjects groups, as well as the change in performance from baseline to retest. Linear
mixed effect modeling enabled the use of all available measurements and is robust in the
presence of unbalanced designs (i.e. missing observations, inconsistent time intervals) and
non-independent correlated data, providing unbiased estimates of covariance parameters
(Verbeke & Molenberghs, 2000; Mallinckrodt et al. 2001; Gueorguieva & Krystal, 2004;
McCulloch et al. 2008). Performance on each neurocognitive test was used as the primary
dependent variable. Fixed effects were group (CHR+T, Meds-matched CHR+NT, Meds-free
CHR+NT, and CNTLs) and time as (baseline and retest) and the interaction between group
and time. The subjects were entered as a random effect. Restricted maximum-likelihood
estimation and Type III tests of fixed effects were used, with a heterogeneous autoregressive
covariance structure. Post-hoc pairwise comparisons were performed with Bonferroni
corrections. Cohen’s d was calculated as the mean difference from the mixed model divided
by the pooled standard deviation [d = (V2 – V1)/σ pooled] and can be interpreted using the
following categories (Cohen, 1988): small = 0.20, medium = 0.50, large = 0.80. A main
effect of time along with a group × time interaction would support evidence of a decline
specific to the converters. Failing to find worsening in neurocognitive performance for the
converters after the onset of psychosis, along with a significant difference between the four
groups would suggest a pre-existing cognitive impairment for those who go on to develop a
full-blown psychotic disorder. The linear mixed-effects models were also used to examine
changes in clinical symptoms (SOPS total positive, negative, disorganized, and general
symptom severity levels) from baseline to retest. Partial correlations (adjusted for group
status) were conducted to examine the relationships between changes in neurocognitive
performance and clinical symptoms over the follow-up period, with the alpha level adjusted
using a Bonferroni correction for the number of tests in this analysis.

Author Manuscript
Author Manuscript

Results
Demographic and clinical characteristics
Table 2 summarizes baseline demographic and clinical characteristics for the CHR+T
subjects along with the two groups of CHR+NT subjects and CNTLs. The four groups were
well-matched, with no differences in baseline age, education level, gender ratio, handedness,
race, ethnicity, and time to the retest assessment. The CNTL group had significantly better
functioning as seen on the GAF, GF:Social and GF:Role compared to all three CHR groups,
while the three CHR groups had comparable levels of functioning at baseline. The CHR+T
group was retested on average 8.04 months (S.D. = 10.26) after the onset of psychosis.

Author Manuscript

Medication treatment at baseline and retest in the CHR+T and Meds-matched CHR+NT
groups were comparable. For both groups at the baseline and retest assessment, 11 out of the
15 subjects (73%) were taking medication. At baseline, five (33.3%) subjects were
prescribed atypical antipsychotics and six (40.0%) anti-depressants. At the retest/postpsychosis assessment, six (40.0%) subjects were prescribed atypical anti-psychotics and five
antidepressants (33.3%).

Psychol Med. Author manuscript; available in PMC 2016 May 01.
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At baseline, CNTLs were significantly different from all three CHR groups, with lower
SOPS positive, negative, disorganized, and general symptom levels. The three CHR groups
had comparable positive and general symptom levels; however, CHR+T subjects showed
significantly worse negative and disorganized symptoms (see Table 2).

Author Manuscript

As shown in Table 3, the linear mixed-models for repeated measures found significant group
differences for all four SOPS symptom scales (all p < 0.001). There were also differential
changes across time in symptom levels, as reflected by significant interactions between visit
and group (see Table 3). The two groups of CHR+NT subjects showed substantial
improvements over time and showed less severe symptoms at retest relative to baseline
assessment. On the other hand, CHR+T subjects showed consistent SOPS symptom levels
over time, with a worsening in positive symptom levels at retest. Post-hoc comparisons
showed that compared to the healthy controls, CHR subjects showed consistently higher
levels of SOPS positive, negative, disorganized, and general symptoms. The Meds-free CHR
+NT and Meds-matched CHR+NT groups had comparable SOPS symptom levels on all four
subscales; however, the CHR+T subjects had higher levels of SOPS positive, negative,
disorganized, and general symptoms compared to the two non-converter groups.
Relationship between changes in clinical symptoms and neurocognitive performance

Author Manuscript

Partial correlations between changes in clinical symptoms and neurocognitive performance
over time indicated that increases in positive symptom severity levels were related to
improvements in processing speed, sustained attention, working memory, and global
cognition (see Supplementary Table S1). Similar relationships were seen also seen for
working memory and negative symptoms as well as with global cognition and disorganized
symptoms, suggesting that increases in symptom severity over the short follow-up period
did not translate into declines in neurocognition. However, these effects did not withstand
correction for multiple comparisons.
Neurocognitive performance
As shown in Fig. 1, each group demonstrated stable neurocognitive and intellectual
performance from baseline to retest. However, compared to the healthy controls and CHR
subjects that did not transition to psychosis, CHR+T subjects showed a consistent
impairment in global neurocognitive and intellectual performance (see Fig. 1a, b) from
baseline (before psychosis) to retest (after psychosis).

Author Manuscript

Estimated marginal means of IQ estimates and each neurocognitive domain derived from the
linear mixed-models are shown in Table 4. Significant group effects were found for all the
neurocognitive domains, including processing speed, verbal memory, executive function,
sustained attention, working memory, and language. Post-hoc pairwise comparisons
demonstrated that the CHR+T group had significantly lower global neurocognitive and
intellectual scores, as well as lower performance on all six neurocognitive domains
compared to CNTLs. The CHR+T group also had worse performance compared to the
Meds-free CHR+NT group on every measure, except executive function and language. The

Psychol Med. Author manuscript; available in PMC 2016 May 01.
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two non-converter groups demonstrated similar performance, without significant
differences.

Author Manuscript

All subject groups demonstrated similar and small improvements (i.e. practice effects) in
performance in many of the domains, with only significant improvements in sustained
attention (p < 0.01) and processing speed (p = 0.03). Trend level improvements were also
seen for the global neurocognitive composite (p = 0.11). Notably, group × visit interactions
were not significant for any domain (see Table 3). Table 5 shows effect size (Cohen’s d)
estimates for changes in intellectual and neurocognitive performance from baseline to retest
for all four subject groups. CHR+T subjects showed similar, small effect sizes compared to
the healthy controls and other CHR+NT comparison groups. One exception was in the
processing speed and attention domains, with healthy controls and Meds-free CHR+NT
subjects showing moderate to large improvements, while CHR+T and Meds-matched CHR
+NT groups showing smaller improvements over time (see Table 5).

Discussion

Author Manuscript

In order to understand the temporal and mechanistic nature of cognitive change following
the onset of psychosis, we prospectively assessed the neurocognitive performance of a group
of clinically at-risk adolescents and young adults before and on average 8 months after the
emergence of full-blown psychosis. True positives, CHR subjects who developed psychosis
after the baseline testing, showed large neurocognitive and intellectual impairments at
baseline, prior to the onset of psychosis, compared to CHR subjects who did not transition to
psychosis. These impairments persisted over the course of the short follow-up period, with
no further deterioration seen after the onset of psychosis. Moreover, the same seems to be
true for antipsychotic and antidepressant treatment, at least in the short-term. On the other
hand, false-positives, subjects ascertained as CHR but who did not transition over the
follow-up period, demonstrated mild to no impairments in neurocognitive and intellectual
performance independent of medication treatment, suggesting that cognitive impairment
during the prodrome is related to the underlying vulnerability to illness, consistent with the
neurodevelopmental model (Weinberger, 1987). Taken together, our results indicate that
cognition is impaired prior to the onset of psychosis and that the onset of psychosis, in and
of itself, does not have a detrimental or ‘neurotoxic’ effect on the course of neurocognition.
Thus, cognitive deficits represent trait risk markers, as opposed to state markers of disease
status and may serve as possible predictors of schizophrenia prior to the onset of the full
illness.

Author Manuscript

At baseline, individuals at CHR who later converted to psychosis showed a global
neurocognitive impairment that mirrored performance levels seen in patients with FEP
(Addington & Addington, 2002; Gonzalez-Blanch et al. 2007). True prodromal subjects
showed a deficit in overall neurocognitive performance that was approximately 1.5 S.D.s
below that of the healthy controls. These impairments persisted after the onset of full-blown
psychosis and did not decline further. Rather, converters to psychosis actually demonstrated
small improvements that were most likely due to practice effects over the follow-up period
that were highly comparable to those seen in both non-converter groups. In addition to a
global neurocognitive impairment, converters also demonstrated stable intellectual deficits
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that were significantly lower than levels seen in the healthy comparison and matched nonconverter groups. In fact, the level of estimated IQ levels seen in the converter group is in
line with a large body of evidence from cohort studies that have associated lower intellectual
performance with a higher risk for developing schizophrenia (David et al. 1997).

Author Manuscript

Converters also showed large impairments of ≥1.5 S.D.s below healthy control levels in
specific areas of neurocognition, including sustained attention, verbal memory, processing
speed, and executive function. Deficits in these domains have been well-documented at
different stages of psychotic illness and have been described as among the core cognitive
deficits in schizophrenia (Green et al. 2004). Performance in sustained visual attention as
measured by the CPT-IP has been found to be heritable, reliable, and stable (independent of
clinical state), representing a promising endophenotype for molecular genetics research in
schizophrenia (Cornblatt & Malhotra, 2001). Impairments in verbal learning and memory
have been shown to make an independent contribution to the prediction of psychosis in CHR
subjects (Lencz et al. 2006). Becker et al. (2010) also found stable deficits in verbal memory
as assessed by the CVLT (Trials 1–5, free recall total correct) in CHR subjects before and
after the onset of psychosis compared to healthy controls. Moreover, in a meta-analytic
review of neurocognitive deficits in first-episode psychosis, Mesholam-Gately et al. (2009)
found that performance on measures of verbal memory, the CVLT included, were among the
poorest compared to healthy levels. Finally, processing speed plays a central role in a variety
of high-order cognitive abilities such as language and reading as well as functional outcomes
in the earliest phases of the illness (Carrión et al. 2011; Meyer et al. 2014). Moreover, due to
the varying task demands (e.g. flexibility, cognitive control, visual scanning, and motor
abilities) used in processing speed measures, deficits in this domain are mostly likely
reflective of dysfunction in spatially distributed and interconnected brain regions that are
linked to the underlying pathophysiology of the illness (Dickinson et al. 2007).
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Indeed, these domain-specific deficits most likely reflect a dysfunction of complex
integrative neural systems that subserve the neuropsychological measures. Our findings are
consistent with mounting evidence of the presence of neurofunctional (Fusar-Poli et al.
2007) and neuroanatomical (Fusar-Poli et al. 2012b) abnormalities prior to the onset of
psychosis in subjects at CHR. Abnormal functional connectivity has been found within brain
networks that underlie domain-specific performance in working memory, executive
function, and processing speed tasks, for example, that include the dorsolateral prefrontal
cortex and anterior cingulate cortex, along with hippocampus and subcortical regions. Future
prospective cohorts with larger CHR converter groups (e.g. North American Prodrome
Longitudinal Study), can examine the relationship between neurocognition along the
pathway towards psychosis and changes in brain morphology that have been documented in
CHR individuals (Pantelis et al. 2003; Cannon et al. 2015).
Limitations
Our findings should be interpreted in light of the following potential limitations. First, our
data cannot rule out cognitive deterioration at other periods along the trajectory of the
disease. The current report only addresses one critical window on the pathway to illness, the
prodrome to shortly after post-psychosis. Decline may occur in childhood or closer to onset
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of the prodrome (Harvey, 2014). Moreover, the relatively short time frame (8 months)
between transition and retest does not rule out further deterioration in the long-term course
of the established illness. Cognitive deterioration may occur years later, possibly
exacerbated by prolonged medication treatment and repeated hospitalizations. However,
recent meta-analyses have not found support for deterioration in older patients with a
chronic course of schizophrenia (Szöke et al. 2008).
Second, it is possible that cognitive functions other than those studied here (e.g. visual
memory) do not deteriorate until psychosis manifests, or become more impaired as the
illness becomes more chronic. Third, the current study only used a combination of the block
design and vocabulary sub-tests to estimate a full-scale IQ. This combination of a verbal and
performance measure did, however, demonstrate excellent stability across time in all four
comparison groups.
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Finally, our ability to detect subtle differences between the groups and to relate individual
differences in cognitive course to clinical outcome may have been hindered by the small
sample of converters. However, the size of the transitioned group is in line with previous
studies that have retested CHR subjects before and after the onset of psychosis (e.g. n = 17,
Becker et al. 2010; n = 16, Wood et al. 2007; n = 10, Woodberry et al. 2013). Furthermore,
the neurocognitive effect sizes from baseline to retest were consistent for each group.
Despite the small sample size, the effect size of cognitive change over time was consistent
across groups, with almost all subjects groups showing small improvements (85% of the
results) in performance over time. These sample sizes are most likely due to the difficulty in
obtaining repeated neurocognitive assessments on individuals who transition to psychosis
during the course of a prospective study, especially after the onset of psychosis.
Nevertheless, this limitation should not necessarily diminish the interpretation of the
primary result, that is, converters as a group did not show decline in neurocognitive function
after the onset of psychosis.
In addition, our study design has a number of strengths compared with previous research.
Converters were well-matched to three separate comparison groups on a number of variables
known to influence cognitive performance. Confounding by age, gender, baseline positive
symptoms, medication at testing, and time to retest are unlikely to explain the key findings.
The nested-case control design also minimizes selection bias as cases and controls were
sampled from the same cohort ensuring the comparability of the groups.
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In summary, the current study does not provide evidence of cognitive deterioration shortly
after the emergence of full-blown psychosis. On the contrary, large cognitive deficits are
apparent in true positives pre- and post-psychosis onset, with no signs of decline, and
therefore appear to be stage-invariant vulnerability traits. Our findings provide further
support for the important role of cognition in the neurodevelopmental processes leading to
psychotic illness that may ultimately serve as a target for preventive intervention.
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Fig. 1.

(a) Global neurocognitive and (b) intellectual performance (±S.E.) at baseline and retest
assessment (post-conversion or matched testing based on duration from baseline) for all four
groups. Global neurocognitive performance was calculated by averaging the six
neurocognitive domains.
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Table 1
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Neurocognitive domains, individual tests, and dependent measures
Verbal memory
California Verbal Learning Test (CVLT)
Total for trials 1–5

Words recalled in trials 1–5

Long delay free recall

Recognition errors

Working memory
Wechsler Intelligence Scale for Children – III/Wechsler
Adult Intelligence Scale – R (WISC-III/WAIS-R)
Digit span forward and backward

Digit sequences recalled

Letter-number span

Number of correct trials

Executive function
Wisconsin Card Sorting Test (WSCT), version 2

Author Manuscript

Perseverative errors

Percentage of perseverative errors;

Categories completed

Number of correctly completed categories

Conceptual level responses

Number of consecutive correct responses in ≥3 runs

Controlled Oral Word Association Test (COWAT)

Words produced in 1 min

Sustained attention
Continuous Performance Test – Identical Pairs (CPT-IP)

d′ (for all stimulus sets)

2, 3, and 4 digits
Processing speed
Trails Making Test, Part A and B

Time to complete trails

WISC-III/WAIS-R digit symbol coding

Symbols accurately coded in 2 min

Animal naming test
Language

Author Manuscript

Wide Range Achievement Test – III (WRAT-III) Reading

Total score for words read correctly

WAIS-R/WISC-III vocabulary

Number of words orally defined

Author Manuscript
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Author Manuscript
17.84 (1.92)
12.00 (1.81)

Age, years, mean (S.D.)

Years of education, mean (S.D.)

13 (82.4)

Handedness, right, n (%)

8.80 (1.08)

–
–

Anxietyb

Substancec

Psychol Med. Author manuscript; available in PMC 2016 May 01.
0 (0.0)
0 (0.0)

Antipsychoticsd

Antidepressantse

0 (0.0)

Antidepressants
18.67 (10.89)

0 (0.0)

Antipsychotics

Time to retest, months, mean (S.D.)

15 (100.0)

No medication

Retest medication, n (%)

15 (100.0)

No medication

Baseline medication, n (%)

–

Mooda

DSM-IV diagnoses, n (%)

8.73 (1.10)

20.641 (19.91)

0 (0.0)

0 (0.0)

15 (100.0)

0 (0.0)

0 (0.0)

15 (100.0)

3 (11.1)

16 (59.3)

15 (55.6)

6.07 (2.46)

5.53 (1.46)

46.07 (6.29)

82.47 (11.70)

Role

7 (25.9)

10 (66.7)

12 (85.2)

12 (80.0)

3 (20.0)

11.20 (1.74)

17.40 (2.18)

2 (11.8)

Social

Global functioning scale, mean (S.D.)

GAF, mean (S.D.)

Hispanic, n (%)

Ethnic origin

White

8 (64.7)

12 (80.0)

Male

Race, n (%)

3 (20.0)

Female

Gender, n (%)

CNTL (n = 15)

Meds-free CHR+NT (n = 15)

Author Manuscript

Characteristic

21.29 (19.30)

5 (33.3)

6 (40.0)

4 (27.0)

6 (40.0)

5 (33.3)

4 (0.27)

0 (0.0)

11 (73.3)

9 (60.0)

4.60 (2.67)

5.80 (1.70)

41.67 (9.03)

2 (13.3)

9 (60.0)

15 (86.7)

12 (80.0)

3 (20.0)

11.20 (1.37)

17.60 (1.50)

Meds-matched CHR+NT (n = 15)

20.49 (20.53)

5 (33.3)

6 (40.0)

4 (27.0)

6 (40.0)

5 (33.3)

4 (0.27)

2 (18.2)

7 (63.6)

5 (45.5)

4.53 (2.33)

4.40 (1.35)

43.00 (8.38)

0 (0.0)

8 (53.3)

11 (90.9)

12 (80.0)

3 (20.0)

11.20 (1.57)

17.56 (1.35)

CHR+T (n = 15)

Author Manuscript

Demographic and clinical characteristics

0.85

0.27

0.66

0.76

<0.001

<0.001

<0.001

0.22

0.76

1.00

0.24

0.32

0.50

p value
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DSM-IV-defined diagnosis of depression, dysthymia, or depressive disorder not otherwise specified (NOS).

Antidepressants included escitalopram, citalopram hydrobromide, fluoxetine, paroxetin, and bupropion.

e

Antipsychotics included risperidone, quetiapine, aripiprazole, and olanzapine.

DSM-IV-defined diagnosis of alcohol, amphetamine, cannabis, cocaine, hallucinogen, nicotine, opioid, or polysubstance related disorder.

d

c

DSM-IV-defined diagnosis of panic disorder, post-traumatic stress disorder, obsessive-compulsive disorder, generalized anxiety disorder, anxiety disorder NOS, or phobias including simple phobias and
social phobia.

b

a

Compared to previous descriptions of CHR+ subjects recruited into the RAP Program (e.g. Carrión et al. 2011, 2013; Olvet et al. 2015), the mean age of the present cohort is slightly older; however, this is
due to matching of the comparison groups to the CHR+T subjects.

CNTL, Healthy comparison subjects; CHR+NT, CHR + subjects who did not transition to psychosis; CHR+T, CHR+ subjects who did transition to psychosis; GAF, Global Assessment of Functioning;
DSM-IV, Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
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1.47 (0.52)
0.82 (0.40)

Time 2

0.53 (0.30)

Time 2

Time 1

0.87 (0.25)

Time 1

1.87 (0.66)

1.80 (0.43)

5.78 (1.09)

8.27 (1.13)

2.32 (0.52)

4.07 (0.57)

6.73 (1.39)

12.33 (1.15)

5.67 (0.71)

9.60 (0.81)

Meds-free CHR+NT

6.93 (1.32)

11.40 (1.15)

2.87 (0.68)

5.40 (0.96)

9.73 (1.23)

13.87 (1.67)

4.53 (.82)

10.00 (.87)

Meds-matched CHR+NT

8.53 (1.17)

10.09 (1.06)

7.49 (1.10)

9.61 (1.18)

16.75 (2.15)

19.92 (1.72)

14.39 (1.47)

12.20 (1.29)

CHR+T

<0.001

<0.001

<0.001

<0.001

Group

<0.001

<0.001

<0.001

<0.001

Visit

0.053

0.011

0.001

<0.001

Group × visit

SOPS total scores are presented along with the standard error of the mean in parentheses and are estimated marginal means derived from the linear mixed models.

SOPS, Scale of Prodromal Symptoms; CNTL, healthy comparison subjects; CHR+NT, CHR+ subjects who did not transition to psychosis; CHR+T, CHR+ subjects who did transition to psychosis.

General

Disorganized

Time 2

Time 1

1.17 (0.42)

Time 2

Negative

1.67 (0.55)

Time 1

Positive

CNTL

Visit

SOPS score

p values

SOPS (positive, negative, disorganized, general) symptom levels by group at baseline and post-psychosis onset/retest

Author Manuscript
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0.66 (0.22)
0.55 (0.26)

Time 1
Time 2

0.06 (0.25)
−0.20 (0.29)

Time 2

0.55 (0.47)

Time 1

0.25 (0.25)

Time 2

0.67 (0.22)

Time 1

0.23 (0.24)

Time 2

0.53 (0.33)

Time 1

0.25 (0.26)

Time 2

Time 2
Time 1

0.37 (0.23)
−0.16 (0.38)

Time 1

0.28 (0.14)

0.23 (0.13)

0.10 (0.14)

0.21 (0.26)

0.18 (0.25)

0.22 (0.26)

−0.51 (0.37)

−0.29 (0.23)

0.14 (0.22)

−0.25 (0.28)

0.41 (0.38)

−0.51 (0.27)

−0.13 (0.38)

−0.13 (0.17)

0.10 (0.15)

−0.06 (0.13)

107.59 (4.84)

107.20 (3.89)

Meds-free CHR+NT

0.33 (0.28)

0.00 (0.31)

0.21 (0.32)

0.17 (0.32)

−0.75 (0.72)

−0.26 (0.32)

−0.2 (0.26)

−0.30 (0.29)

−0.52 (0.52)

−0.64 (0.34)

0.40 (0.31)

−0.30 (0.27)

−0.14 (0.25)

−0.29 (0.23)

106.55 (5.06)

104.53 (4.22)

Meds-matched CHR+NT

−0.88 (0.48)

−0.92 (0.35)

−1.50 (0.34)

−1.23 (0.37)

−0.87 (0.45)

−1.44 (0.47)

−1.24 (0.38)

−1.60 (0.31)

−1.88 (0.39)

−1.98 (0.37)

−1.26 (0.31)

−1.82 (0.33)

−1.25 (0.33)

−1.44 (0.32)

92.13 (3.52)

92.60 (3.48)

CHR+T

0.02

0.002

0.05

0.001

<0.001

0.001

<0.001

0.002

Group

0.82

0.35

0.85

0.01

0.03

0.34

0.11

0.82

Visit

0.74

0.80

0.29

0.73

0.17

0.15

0.85

0.97

Group × visit

Psychol Med. Author manuscript; available in PMC 2016 May 01.

Estimated full-scale IQ scores were derived from the vocabulary and block design subscales of the Wechsler Intelligence Scale for Children – Third Edition for subjects aged <16 years and from the
Wechsler Adult Intelligence Scale – Revised for subjects aged ≥16 years.

a

Scores are presented as z scores (standard error of the mean) and are estimated marginal means derived from the linear mixed models. A main effect of time along with a group × time interaction would
support evidence of a decline specific to the converters. Failing to find worsening in neurocognitive performance for the converters after the onset of psychosis, along with a significant difference between
the four groups would suggest a pre-existing cognitive impairment for those who go on to develop a full-blown psychotic disorder.

CNTL, Healthy comparison subjects; CHR+NT, CHR+ subjects who did not transition to psychosis; CHR+T, CHR+ subjects who did transition to psychosis.

Language

Working memory

Executive function

Sustained attention

Processing speed

Verbal memory

Time 2

Time 1

111.50 (2.34)

Time 2

Global neurocogitive composite

111.80 (2.89)

Time 1

IQa

CNTL

Visit

Variable

p values

Intellectual (IQ) performance and neurocognitive Z scores by group at baseline and post-psychosis onset/retest
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Effect sizes (Cohen’s da) of neurocognitive change over time for the four subject groups
Variable

CNTL

Meds-free CHR+NT

Meds-matched CHR+NT

CHR+T

IQ

0.03

0.02

0.10

0.04

Global neurocognitive composite

0.09

0.30

0.13

0.15

Verbal memory

0.32

0.00

0.45

0.37

Processing speed

0.22

0.66

0.06

0.07

Sustained attention

0.50

0.35

0.05

0.07

Executive function

0.16

0.15

0.17

0.30

Working memory

0.21

0.04

0.03

0.16

Language

0.10

0.11

0.22

0.02

CNTL, Healthy comparison subjects; CHR+NT, CHR+ subjects who did not transition to psychosis; CHR+T, CHR+ subjects who did transition to
psychosis.
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a

Cohen (1988) recommended the following categories for interpreting effect sizes: small = 0.2, medium = 0.5, and large = 0.8.
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